Recent discussions on X about Summit Therapeutics (SMMT) have centered around the mixed results from the Phase III HARMONi trial for their lung cancer drug, ivonescimab. Posts on the platform highlight a significant drop in stock price following the release of data that showed no substantial improvement in overall survival compared to chemotherapy in some patient groups. Despite this, some users remain optimistic, pointing to positive trends in progression-free survival and analyst price targets as high as $40.
The conversation on X also reflects on insider buying, with reports of a major executive purchase sparking interest among investors. Additionally, reiterations of 'Buy' and 'Market Outperform' ratings by prominent financial firms have fueled debates about the stock’s future trajectory. The mix of setbacks and hopeful signals keeps the dialogue dynamic and closely watched.
Note: This discussion summary was generated from an AI condensation of post data.
Summit Therapeutics Insider Trading Activity
Summit Therapeutics insiders have traded $SMMT stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SMMT stock by insiders over the last 6 months:
- ROBERT W DUGGAN (Co-Chief Executive Officer) has made 2 purchases buying 338,394 shares for an estimated $5,984,755 and 0 sales.
- MAHKAM ZANGANEH (Co-Chief Executive Officer) has made 2 purchases buying 338,394 shares for an estimated $5,984,755 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Summit Therapeutics Hedge Fund Activity
We have seen 138 institutional investors add shares of Summit Therapeutics stock to their portfolio, and 146 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAKER BROS. ADVISORS LP added 9,298,109 shares (+38.1%) to their portfolio in Q2 2025, for an estimated $197,863,759
- VANGUARD GROUP INC removed 2,966,835 shares (-25.5%) from their portfolio in Q2 2025, for an estimated $63,134,248
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,652,656 shares (-40.5%) from their portfolio in Q2 2025, for an estimated $56,448,519
- BALYASNY ASSET MANAGEMENT L.P. removed 1,703,180 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $36,243,670
- BLACKROCK, INC. removed 1,550,889 shares (-18.5%) from their portfolio in Q2 2025, for an estimated $33,002,917
- NORGES BANK added 1,289,862 shares (+1289.9%) to their portfolio in Q2 2025, for an estimated $27,448,263
- APEIRON CAPITAL LTD added 1,200,941 shares (+inf%) to their portfolio in Q2 2025, for an estimated $25,556,024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Summit Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $SMMT in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/08/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/08/2025
- JMP Securities issued a "Market Outperform" rating on 08/19/2025
- Evercore ISI Group issued a "Outperform" rating on 08/12/2025
- UBS issued a "Buy" rating on 07/01/2025
- Leerink Partners issued a "Underperform" rating on 06/11/2025
- Goldman Sachs issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for Summit Therapeutics, check out Quiver Quantitative's $SMMT forecast page.
Summit Therapeutics Price Targets
Multiple analysts have issued price targets for $SMMT recently. We have seen 12 analysts offer price targets for $SMMT in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $50.0 on 09/08/2025
- Brad Canino from Guggenheim set a target price of $40.0 on 09/04/2025
- Reni J. Benjamin from JMP Securities set a target price of $40.0 on 09/03/2025
- Kelsey Goodwin from Piper Sandler set a target price of $21.0 on 08/19/2025
- Cory Kasimov from Evercore ISI Group set a target price of $34.0 on 08/12/2025
- David Dai from UBS set a target price of $30.0 on 07/01/2025
- Daina Graybosch from Leerink Partners set a target price of $12.0 on 06/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
